
Peter Arlett

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5573378/publications.pdf Version: 2024-02-01



DETED ADIETT

#	Article	IF	CITATIONS
1	Realâ€World Data for Regulatory Decision Making: Challenges and Possible Solutions for Europe. Clinical Pharmacology and Therapeutics, 2019, 106, 36-39.	2.3	180
2	Randomized Controlled Trials Versus Real World Evidence: Neither Magic Nor Myth. Clinical Pharmacology and Therapeutics, 2021, 109, 1212-1218.	2.3	97
3	Realâ€World Evidence in EU Medicines Regulation: Enabling Use and Establishing Value. Clinical Pharmacology and Therapeutics, 2022, 111, 21-23.	2.3	87
4	EudraVigilance Medicines Safety Database: Publicly Accessible Data for Research and Public Health Protection. Drug Safety, 2018, 41, 665-675.	1.4	73
5	Promoting and Protecting Public Health: How the European Union Pharmacovigilance System Works. Drug Safety, 2017, 40, 855-869.	1.4	69
6	Evaluation of the effectiveness of risk minimization measures. Pharmacoepidemiology and Drug Safety, 2012, 21, 896-899.	0.9	54
7	Proactively managing the risk of marketed drugs: experience with the EMA Pharmacovigilance Risk Assessment Committee. Nature Reviews Drug Discovery, 2014, 13, 395-397.	21.5	42
8	European Medicines Agency review of postâ€authorisation studies with implications for the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance. Pharmacoepidemiology and Drug Safety, 2011, 20, 1021-1029.	0.9	38
9	Registries in European postâ€marketing surveillance: a retrospective analysis of centrally approved products, 2005–2013. Pharmacoepidemiology and Drug Safety, 2017, 26, 1442-1450.	0.9	32
10	Increasing scientific standards, independence and transparency in postâ€authorisation studies: the role of the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance. Pharmacoepidemiology and Drug Safety, 2012, 21, 690-696.	0.9	27
11	Regulatory and health technology assessment advice on postlicensing and postlaunch evidence generation is a foundation for lifecycle data collection for medicines. British Journal of Clinical Pharmacology, 2020, 86, 1034-1051.	1.1	26
12	Study Design and Evaluation of Risk Minimization Measures: A Review of Studies Submitted to the European Medicines Agency for Cardiovascular, Endocrinology, and Metabolic Drugs. Drug Safety, 2018, 41, 191-202.	1.4	25
13	Improving the Safety of Medicines in the European Union: From Signals to Action. Clinical Pharmacology and Therapeutics, 2020, 107, 521-529.	2.3	24
14	Pharmacovigilance 2030. Clinical Pharmacology and Therapeutics, 2020, 107, 89-91.	2.3	20
15	A European multicentre drug utilisation study of the impact of regulatory measures on prescribing of codeine for pain in children. Pharmacoepidemiology and Drug Safety, 2019, 28, 1086-1096.	0.9	13
16	Can We Rely on Results From IQVIA Medical Research Data UK Converted to the Observational Medical Outcome Partnership Common Data Model?. Clinical Pharmacology and Therapeutics, 2020, 107, 915-925.	2.3	11
17	What are the patients' and health care professionals' understanding and behaviors towards adverse drug reaction reporting and additional monitoring?. Pharmacoepidemiology and Drug Safety, 2021, 30, 334-341.	0.9	10
18	Exploring the opportunities for alignment of regulatory postauthorization requirements and data required for performance-based managed entry agreements. International Journal of Technology Assessment in Health Care, 2021, 37, e83.	0.2	10

Peter Arlett

#	Article	IF	CITATIONS
19	The European Medicines Agency's use of prioritised independent research for best evidence in regulatory action on diclofenac. Pharmacoepidemiology and Drug Safety, 2014, 23, 431-434.	0.9	8
20	Measuring the impact of risk communications: Robust analytical approaches are key. British Journal of Clinical Pharmacology, 2020, 86, 635-636.	1.1	8
21	Does additional monitoring status increase the reporting of adverse drug reaction <scp>s</scp> ? An interrupted time series analysis of <scp>EudraVigilance</scp> data. Pharmacoepidemiology and Drug Safety, 2021, 30, 350-359.	0.9	5
22	Periodic Benefit-Risk Evaluation Report: A European Union Regulatory Perspective. Pharmaceutical Medicine, 2014, 28, 309-315.	1.0	4
23	Ability of Primary Care Health Databases to Assess Medicinal Products Discussed by the European Union Pharmacovigilance Risk Assessment Committee. Clinical Pharmacology and Therapeutics, 2020, 107, 957-965.	2.3	3
24	Building an Evidence Base on the Place of Industry-Sponsored Programs in Drug Safety Surveillance. Drug Safety, 2019, 42, 581-582.	1.4	1
25	International Collaboration in Realâ€World Evidence Generation for Direct Acting Oral Antiâ€Coagulants. Clinical Pharmacology and Therapeutics, 2021, 109, 299-301.	2.3	1